Disappearance of tumor staining on contrast-enhanced computed tomography (CE-CT) [15] or on contrast-enhanced ultrasound [16,17], decrease in alpha-fetoprotein (AFP) level [18–21] and decrease in vascular endothelial growth factor level [22] have been reported as indicators of good prognosis and the anti-tumor effect in the early post-dose period of sorafenib therapy. This evidence concerns the gene AFP and neoplasm.